Post by Leica Biosystems

AI is accelerating the rise of multimodal diagnostics, bringing together IHC, H&E, and other modalities to deliver a more precise view of disease biology. Following Part 1 recently published, Part 2 continues the conversation with Jorge Reis-Filho from AstraZeneca, alongside leaders from Danaher Corporation and Leica Biosystems, to discuss how AI is advancing biomarker interpretation and therapy decision support. Key takeaways: • More accuracy and consistency across labs for critical treatment thresholds • Multimodal insights that go beyond what any single test can reveal • Ecosystem partnerships that move innovation from research into scalable workflows At Leica Biosystems, we’re building the open digital pathology foundation—combining Aperio whole slide imaging and its open marketplace for AI applications—to help partners bring computational pathology into real world workflows. Read Part 2 of “Breaking the Biomarker Bottlenecks”: https://lnkd.in/e5Wc56G4 #DanaherNews #CompanionDiagnostics #PrecisionMedicine #AI